COVID-19-Related Hypercoagulability as a Long-term Complication in SARS-CoV-2: Lessons from SARS and MERS
Immunology and Genetics Journal · 07.07.2024
DOI: 10.18502/igj.v5i3.16036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology and Genetics Journal, online erschienen am 07.07.2024. Verfasst von Elahe Mohammadi Jorjafki und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a various clinical and laboratory finding in affected patients. Similar to the previous outbreak, patients with SARS-CoV-2 showed elevated levels of D-dimer, thrombocytopenia, prolonged prothrombin time, and the activated partial thromboplastin time. Meanwhile, two lethal coagulation disorders of disseminated intravascular coagulation and pulmonary embolism have already been reported in patients with SARS-CoV-2. Although further cohort studies are needed to document long-term complications, considering the similar pathogenicity of SARS-CoV and SARS-CoV-2, the same chronic cardiovascular impairments could be expected.
Zitieren
APA
Jorjafki, E. M., Karimizadeh, Z., Shahi, A., & Sohrabi, H. (2024). COVID-19-Related Hypercoagulability as a Long-term Complication in SARS-CoV-2: Lessons from SARS and MERS. Immunology and Genetics Journal. https://doi.org/10.18502/igj.v5i3.16036
Vancouver
Jorjafki EM, Karimizadeh Z, Shahi A, Sohrabi H. COVID-19-Related Hypercoagulability as a Long-term Complication in SARS-CoV-2: Lessons from SARS and MERS. Immunology and Genetics Journal. 2024. doi:10.18502/igj.v5i3.16036
BibTeX
@article{Jorjafki2024,
author = {Jorjafki, Elahe Mohammadi and Karimizadeh, Zahra and Shahi, Ali and Sohrabi, Hanye},
title = {COVID-19-Related Hypercoagulability as a Long-term Complication in SARS-CoV-2: Lessons from SARS and MERS},
journal = {Immunology and Genetics Journal},
year = {2024},
doi = {10.18502/igj.v5i3.16036}
}
EUVIMED